Nuvalent Inc. Class A Common Stock

Nuvalent Inc. a clinical stage biopharmaceutical company engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520 a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors which is under Phase I development; NVL-655 a brain-penetrant ALK-selective inhibitor to address the clinical challenges of emergent treatment resistance central nervous system-related adverse events and brain metastases that might limit the use of first- second- and third-generation ALK inhibitors that is under Phase ½ clinical trial; and NVL-330 a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20 brain metastases and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR which is ongoing IND-enabling studies. The company was incorporated in 2017 and is headquartered in Cambridge Massachusetts.